




International Study for Prediction of Optimized Treatment

- iSPOT

Brain Resource has diverse proprietary platforms to test drugs, identify objective personalized Markers (to predict who will best respond to what drug) and discover new drugs. This includes the largest current international Study to Predict Optimized Treatment (iSPOT).

iSPOT is an effectiveness trial with the primary aim of identifying Genetic and Brain Markers (including Genetics; MRI, DTI & fMRI; Cognition; EEG, ERP; Heart Rate Variability and Self Report, see the measures and potential Markers below) which best predict treatment response.

What are the measures?




Genetics



MRI, DTI & fMRI



Cognition



EEG & ERP



Heart Rate
Variability



Behavior &
Self Report

Who is participating in iSPOT?

This is an open-label, randomized trial recruiting 2,000 subjects with major depressive disorder across multiple international sites. Subjects are randomised to one of the three most used treatments : Escitalopram, Sertraline or Venlafaxine XR. A group of matched healthy controls (n = 672) is also being enrolled. Site visits are at baseline and 8 weeks after treatment. Regular clinical monitoring will occur for a further 44 weeks.

Over 500 subjects have already completed the 8 week re-assessment in the US, Europe and Australian sites.

iSPOT-D has achieved substantial global recognition facilitated by Brain Resource's Standardization and Integrative methodology, the successful recruitment of over patients and by having Dr A. John Rush, the world renowned Psychiatrist who was the Principal Investigator of the National Institutes of Mental Health (Washington) STAR*D trial, as Head of the iSPOT-D Publication Committee.

For more information:

If you have any other questions, please contact info@BrainResource.com.